FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting

The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.